Reid Robison, M.D., M.B.A.
Principal Investigator, CRI Lifetree Salt Lake City
Reid Robison, M.D., M.B.A. is a Research Psychiatrist at CRI Lifetree in Salt Lake City, Utah, where he is the Principal Investigator Rese. Dr. Robison also currently serves as the Medical Director of Consultation-Liaison Psychiatry at Intermountain Medical Center, Utah's largest hospital. He is a board-certified psychiatrist, with fellowship training in clinical research, biomedical informatics and neurodevelopmental genetics.
Prior to medical school, Dr. Robison studied neuroscience at Brigham Young University where he was investigating the effects of neuropeptides on weight loss in animal models. Dr. Robison then attended medical school, residency and fellowship training at the University of Utah. After fellowship training, Dr. Robison joined the tenure track faculty at the University of Utah Department of Psychiatry where he served as Associate Director of the Psychiatry Research Clinic running clinical trials in psychopharmacology, and Co-Directing the University of Utah Psychiatric Genetics lab conducting biomarker, genomics and pharmacogenetics research.
Dr. Robison co-founded Anolinx in 2011, a healthcare data analytics firm which was acquired in 2012. As a founding partner in Anolinx, Dr. Robison conducted pharmacoepidemiologic, pharmacovigilance and EHR-based outcomes studies for large pharmaceutical companies, including consulting on a number compounds throughout the drug development life cycle. Dr. Robison also founded Clinical Methods in 2007, a Phase I-IV CNS research site in Salt Lake City, Utah, and subsequently transitioned all of his clinical research efforts to CRI-Lifetree's large and well-established Utah research site in 2012.
He has over 15 peer-reviewed publications in the fields of clinical research & biomarkers, and is often sought after as a reviewer for journals, a speaker for academic conferences, and a thought leader in psychopharmacology. Dr. Robison has been the Principal Investigator on over 25 clinical trials, including both pediatric and adult studies, covering indications such as Mood & Anxiety Disorders (Depression, Bipolar, PTSD, GAD), Psychotic Disorders (Schizophrenia, Psychotic Depression), Autism, ADHD, Mild Cognitive Impairment, Alzheimer's and more.